Delivered-To: tjphuhs@gmail.com Received: by 2002:a05:622a:2b4e:b0:50f:b801:ff26 with SMTP id hb14csp2099164qtb; Mon, 11 May 2026 15:04:20 -0700 (PDT) X-Received: by 2002:a05:6214:4589:b0:8a5:104b:e385 with SMTP id 6a1803df08f44-8bc45e1f618mr418407216d6.35.1778537060790; Mon, 11 May 2026 15:04:20 -0700 (PDT) ARC-Seal: i=1; a=rsa-sha256; t=1778537060; cv=none; d=google.com; s=arc-20240605; b=XvjeFA3foMJsjRiEfp7B4wc3Ks5l0qrv3BwPAOXjS78DX32ckxh5ND65+4LAJz85t+ dmdJvO6Hz7mcCX+CFP1UsaD8Km5gB3ReImYfA6LaFPhnl1WAJ3meM7IbguGJaQppf0WX gDwCirXq5rVHfV8Wzddnfs+FxF7RzKRzOMTmAwO3q9T1egK+TVoztDrBcQwRRUSUk6Kk ilPkGzFkgmdFmr8IDBaxg/Zpy486P6MIKRzyi85+FlPfj9ghU/ycmHllHTblMUWUbNb4 uPituFsmyWJf95WND46dkkzmNUjJ5vQRzRaM0nd63Nb/Z4brz2YBEx6JFuTuJk7HsRKm AU9Q== ARC-Message-Signature: i=1; a=rsa-sha256; c=relaxed/relaxed; d=google.com; s=arc-20240605; h=message-id:date:mime-version:sid:subject:reply-to :list-unsubscribe-post:list-unsubscribe:from:feedback-id:to :dkim-signature:dkim-signature; bh=MEDhvBZkhkikRNJ1VE5RM0D6z4nnutmMkuOAyj3N48I=; fh=Hcu5VqhndQNvtVhwbc8tr7JrSOSQJms/+lG2L+E9gBs=; b=WjK/0Yi1XE73dfPiPwjs9ix5n2k0P10aOgHiabTxvTretokGk3T9VDBlTkri1H6Mef YwvdGkG9z1NqiH7QbV1z+lUWwTpfHS25A0LrwewC0qeeS3B9Zh5BopvUSJ0oTe/qTIX/ PnrWitfl96VCokZH598jOwSYagK47zJSuwjrKZJrkvEcAVwEXLzAt80eiRaXhZCru5dM xqiADR+rOrCmhOQW1duVhcCo1RwVO6KAmzeigLv+pkJfk9AozNO5JxOVja8mmj3FwDwW UJ9ZOLEH3zpsl1c0af7F01cXldSSsylp7bUkoVD1nE3toiT4wInnms5ja9TOLsAS4L/K W2AA==; dara=google.com ARC-Authentication-Results: i=1; mx.google.com; dkim=pass header.i=@bhmta.beehiiv.com header.s=bh header.b=sSpk0rA6; dkim=pass header.i=@mail.beehiiv.com header.s=bh header.b=UQs3LxOF; spf=pass (google.com: domain of bounces+tjphuhs=gmail.com@bh.mail.beehiiv.com designates 69.67.186.21 as permitted sender) smtp.mailfrom="bounces+tjphuhs=gmail.com@bh.mail.beehiiv.com"; dmarc=pass (p=REJECT sp=REJECT dis=NONE) header.from=beehiiv.com Return-Path: Received: from bh186-21.smtp-out.beehiivmail.net (bh186-21.smtp-out.beehiivmail.net. [69.67.186.21]) by mx.google.com with ESMTPS id 6a1803df08f44-8bcb8f0620bsi214842566d6.202.2026.05.11.15.04.20 for (version=TLS1_3 cipher=TLS_AES_256_GCM_SHA384 bits=256/256); Mon, 11 May 2026 15:04:20 -0700 (PDT) Received-SPF: pass (google.com: domain of bounces+tjphuhs=gmail.com@bh.mail.beehiiv.com designates 69.67.186.21 as permitted sender) client-ip=69.67.186.21; Authentication-Results: mx.google.com; dkim=pass header.i=@bhmta.beehiiv.com header.s=bh header.b=sSpk0rA6; dkim=pass header.i=@mail.beehiiv.com header.s=bh header.b=UQs3LxOF; spf=pass (google.com: domain of bounces+tjphuhs=gmail.com@bh.mail.beehiiv.com designates 69.67.186.21 as permitted sender) smtp.mailfrom="bounces+tjphuhs=gmail.com@bh.mail.beehiiv.com"; dmarc=pass (p=REJECT sp=REJECT dis=NONE) header.from=beehiiv.com X-BmtaRef: eyJfQF8iOiJcXF8vIiwicmVjaXBpZW50IjoidGpwaHVoc0BnbWFpbC5jb20iLCJ4X2xpc3RfaWQiOiJmZDQxNjMwZS1lOTFmLTQ2ZDktYTI3NC1iNzQwZGFiNzU2ZDIiLCJ4X3N1YnNjcmliZXJfaWQiOiI5YzQwZDYzOS02ZTFkLTQyOTItYTlkNy0wZTRjYmJiNWQ1ZGIifQ== DKIM-Signature: v=1; a=rsa-sha256; d=bhmta.beehiiv.com; s=bh; c=relaxed/relaxed; bh=MEDhvBZkhkikRNJ1VE5RM0D6z4nnutmMkuOAyj3N48I=; h=from:subject:mime-version:content-type:content-transfer-encoding: list-unsubcribe:feedback-id:list-unsubscribe-post:reply-to:to:cc: content-type:feedback-id:from:subject:to; t=1778537060; b=sSpk0rA6cqrwkbq4rYbZ40tph0ec7GxJB0m9OPBKn9S8/OSfL/58FgO4V51JT/j9mr31G0fQt 88BgszZ01/40VlewcgT1lS4RWvxNqThAqPhDyOgws8ri1kvFgsoSgM9EbcRisez6wtThRzt8ykR hYkd3qnj0c31erlp18+L5jw/3ImvTFadZcgIME46oCl6s2u7k2MhAWPjmgcZRKWkYqHLNHT+ZQN 4A/7voYHaXkiuxO2VeWRKDh3XTvuq2ClTXQ8dC8msjWHg2ZCURPnFW6CS4DwwhaAq6Q4B46Q+UQ XANd1BUxbRs5h4PbkT2SsMU4ePoohDf3wuCyA55R3T/A==; DKIM-Signature: v=1; a=rsa-sha256; d=mail.beehiiv.com; s=bh; c=relaxed/relaxed; bh=MEDhvBZkhkikRNJ1VE5RM0D6z4nnutmMkuOAyj3N48I=; h=from:subject:mime-version:content-type:content-transfer-encoding: list-unsubcribe:feedback-id:list-unsubscribe-post:reply-to:to:cc: content-type:feedback-id:from:subject:to; t=1778537060; b=UQs3LxOF0Q2KNf5PzKk6Uo7EWn54gD+GK578u5SJpiyGohE+PnW0I5qKJO8oG0i564NmYgFh9 LmSYxlHTdOzxqF+G4GkD+5WyhJiKdz4GGmtmyhXpdz5mxTrVqKFqa5nNOf23bFF4vTrYftAe+OS cP9BBV9Slyd6aKRRWjhHoEleMVjD6geA9fcJmH6+Lwg82tKeQUfjv5k75CkrVIwP0UtIILHY1TO S+D41yFkS4hmGSqhP9zt2oBVJaAdayWiCuGBHZdPAgCIkwZNHzI4rBEyI8OYsZilRaQKLa7m4PH DK5Vpg31WZE8U+QXu1G6eiSZ6UPhMkXpgFLnD2zFd84A==; Received: from mail.beehiiv.com by bhmta(mta19) with HTTP id <5ca480b14d8511f1b95312609588b57b> for ; Mon, 11 May 2026 22:04:20 +0000 Content-Type: multipart/alternative; boundary="dPzjRFRLR0yd1+YAIDzoEg" To: "tjphuhs@gmail.com" Feedback-ID: 68d4d5b7-7ff1-4812-b13f-49ff15f24009:newsletter:fd41630e-e91f-46d9-a274-b740dab756d2:c8f61fda6a60803 From: Hunter Williams List-Unsubscribe: , List-Unsubscribe-Post: List-Unsubscribe=One-Click Reply-To: =?utf-8?Q?Hunter=27s_Health_Hacks?= Subject: The Double-Edged Sword of Dopamine X-Batch-Id: bfadfe68-475c-42fe-af14-57856cd5e58f X-Subscriber-ID: 9c40d639-6e1d-4292-a9d7-0e4cbbb5d5db X-Subscription-ID: 663283104 sId: fd41630e-e91f-46d9-a274-b740dab756d2 x-beehiiv-ids: {"account_name":"https://huntershealthhacks.beehiiv.com/","campaign_id":"68d4d5b7-7ff1-4812-b13f-49ff15f24009","category":"newsletter","email_generated_at":1778537059,"user_id":"fd41630e-e91f-46d9-a274-b740dab756d2"} x-beehiiv-type: newsletter x-list-id: fd41630e-e91f-46d9-a274-b740dab756d2 x-list-owner: x-newsletter: https://huntershealthhacks.beehiiv.com/p/the-double-edged-sword-of-dopamine x-newsletter-id: https://huntershealthhacks.beehiiv.com/ x-newsletter-signup: https://huntershealthhacks.beehiiv.com/subscribe Mime-Version: 1.0 Date: Mon, 11 May 2026 22:04:20 +0000 Message-ID: <20260511.220420.21ed1037@mta19> --dPzjRFRLR0yd1+YAIDzoEg Content-Type: text/plain; charset="utf-8" Content-Transfer-Encoding: quoted-printable Happy Monday!=0A=0A[A new paper just dropped in ](https://www.nature.com/ar= ticles/s41586-026-10444-4)_[Nature](https://www.nature.com/articles/s41586-= 026-10444-4)_ that finally explains something the real-world data has been = screaming for two years ([Click here to read it](https://www.nature.com/art= icles/s41586-026-10444-4)).=0A=0APeople on GLP-1s are drinking less. Smokin= g less. Gambling less. Shopping less. Some of them are saying food doesn't = taste the same anymore.=0A=0ANobody knew why.=0A=0AUntil now.=0A=0AThe rese= archers built a humanized mouse that responds to the small-molecule GLP-1s = like orforglipron and danuglipron, then set out to find what these drugs ac= tually do in the brain. =0A=0AWhat they found is a brand new circuit, and i= t changes how we should think about this entire class of medications.=0A=0A= Here's the short version. In addition to turning down hunger, GLP-1s turn d= own **dopamine**. =0A=0ASpecifically, they reduce dopamine release in the n= ucleus accumbens (the brain's main reward hub) when you eat something pleas= urable.=0A=0ASame drug. Two faces. Let=E2=80=99s walk through it.=0A=0A=E2= =80=9C**_Two sentence summary:_**_ _GLP-1 drugs go beyond appetite suppress= ion. They turn down dopamine across the board, which is why they quiet crav= ings for alcohol, food, and gambling, and also why some long-term users say= their joy has gone flat.=E2=80=9C =E2=80=94 =0A=0A=E2=80=94=E2=80=94=E2=80= =94=E2=80=94=E2=80=94=E2=80=94=E2=80=94=E2=80=94=E2=80=94=E2=80=94=E2=80=94= =E2=80=94=E2=80=94=E2=80=94=E2=80=94=E2=80=94=E2=80=94=E2=80=94=E2=80=94=E2= =80=94=E2=80=94=E2=80=94=E2=80=94=E2=80=94=E2=80=94=E2=80=94=E2=80=94=0A=0A= **The New Circuit**=0A=0AFor years, we've known GLP-1s work on the hindbrai= n and hypothalamus. =0A=0AThat's the "I'm full" signal. Classic homeostatic= feeding.=0A=0AThis paper found a second circuit running in parallel.=0A=0A= Hindbrain =E2=86=92 central amygdala =E2=86=92 VTA =E2=86=92 nucleus accumb= ens.=0A=0AThe central amygdala is the new piece. When the researchers selec= tively knocked out the GLP-1 receptor in those amygdala neurons, the drugs = basically lost their ability to suppress _pleasurable_ eating. Mice still g= ot full on normal chow. They just didn't lose interest in the high-fat food= .=0A=0ASo there are two parallel systems running simultaneously.=0A=0AOne s= ays, "Stop eating, you have enough calories."=0A=0AThe other says, "This is= n't as rewarding as you thought it was."=0A=0AGLP-1s hit both.=0A=0A=E2=80= =94=E2=80=94=E2=80=94=E2=80=94=E2=80=94=E2=80=94=E2=80=94=E2=80=94=E2=80=94= =E2=80=94=E2=80=94=E2=80=94=E2=80=94=E2=80=94=E2=80=94=E2=80=94=E2=80=94=E2= =80=94=E2=80=94=E2=80=94=E2=80=94=E2=80=94=E2=80=94=E2=80=94=E2=80=94=E2=80= =94=E2=80=94=0A=0A**Dopamine**=0A=0AThis is the part that should grab your = attention.=0A=0AThey used a fluorescent dopamine sensor implanted in the nu= cleus accumbens of live mice. Then they fed the mice a high-fat diet and wa= tched what happened in real time.=0A=0AVehicle mice showed a big dopamine s= pike at the moment of food retrieval. Classic reward signal. The kind of re= lease that says "yes, do that again."=0A=0AMice on liraglutide, danuglipron= , and orforglipron all showed the same thing.=0A=0AA flatter peak. A smalle= r sustained release. **Less dopamine, period.**=0A=0AThis was true for all = three drugs, peptide and small molecule alike. Which means it's a class eff= ect, not specific to one compound. The mechanism is built into how GLP-1 si= gnaling works.=0A=0A=E2=80=94=E2=80=94=E2=80=94=E2=80=94=E2=80=94=E2=80=94= =E2=80=94=E2=80=94=E2=80=94=E2=80=94=E2=80=94=E2=80=94=E2=80=94=E2=80=94=E2= =80=94=E2=80=94=E2=80=94=E2=80=94=E2=80=94=E2=80=94=E2=80=94=E2=80=94=E2=80= =94=E2=80=94=E2=80=94=E2=80=94=E2=80=94=0A=0A**The Upside**=0A=0AIf you've = been paying attention to real-world data on semaglutide and tirzepatide, yo= u've seen the reports.=0A=0AAlcohol use disorder incidence drops in people = who get prescribed these drugs.=0A=0ACannabis use disorder drops.=0A=0APeop= le report less compulsive shopping, less doomscrolling, and less mindless l= ate-night snacking.=0A=0AFor a long time, nobody could explain it. =0A=0ASo= me researchers thought that weight loss alone improved mood. =0A=0AOthers t= hought it was the gut-brain axis doing something we hadn't mapped.=0A=0AThi= s paper gives us the actual receipts.=0A=0AThe drugs are blunting the rewar= d signal coming from the VTA into the accumbens. That's the same circuit th= at fires when an addict gets a hit. The same circuit that fires when you sl= am a pint of ice cream. The same circuit that fires when a slot machine pay= s out.=0A=0ATurn that signal down across the board, and a lot of compulsive= behavior loses its grip.=0A=0AThis is genuinely huge for the addiction med= icine world.=0A=0A=E2=80=94=E2=80=94=E2=80=94=E2=80=94=E2=80=94=E2=80=94=E2= =80=94=E2=80=94=E2=80=94=E2=80=94=E2=80=94=E2=80=94=E2=80=94=E2=80=94=E2=80= =94=E2=80=94=E2=80=94=E2=80=94=E2=80=94=E2=80=94=E2=80=94=E2=80=94=E2=80=94= =E2=80=94=E2=80=94=E2=80=94=E2=80=94=0A=0A**The Downside**=0A=0ABut the dop= amine reduction isn't selective.=0A=0AThe drug doesn't know the difference = between a craving for vodka and a craving for your kid's birthday cake. =0A= =0AIt doesn't know the difference between the dopamine surge from a junk-fo= od binge and the dopamine surge from a meal with people you love.=0A=0AIt j= ust turns the signal down.=0A=0ASo when you hear complaints from long-term = GLP-1 users, the pattern starts making sense.=0A=0A"Food doesn't taste the = same."=0A=0A"I don't really get excited about things anymore."=0A=0A"I lost= weight, but I also kind of lost my joy."=0A=0AThe mechanism does exactly w= hat it's designed to do, just applied to things you actually wanted to keep= enjoying.=0A=0A=E2=80=94=E2=80=94=E2=80=94=E2=80=94=E2=80=94=E2=80=94=E2= =80=94=E2=80=94=E2=80=94=E2=80=94=E2=80=94=E2=80=94=E2=80=94=E2=80=94=E2=80= =94=E2=80=94=E2=80=94=E2=80=94=E2=80=94=E2=80=94=E2=80=94=E2=80=94=E2=80=94= =E2=80=94=E2=80=94=E2=80=94=E2=80=94=0A=0A**Final Thoughts**=0A=0AGLP-1s ar= e the most important pharmaceutical development in metabolic medicine in 40= years. I'm not going to pretend otherwise.=0A=0ABut we must stop talking a= bout them like they're just appetite suppressants with some bonus benefits.= =0A=0AThey're reward modulators. Appetite suppression is one downstream ef= fect of a much larger mechanism.=0A=0AIf you're using one of these drugs, o= r thinking about it, the question to ask yourself isn't just "will this hel= p me lose weight." =0A=0AIt's "am I okay turning down my dopamine response = to everything for the duration that I'm on this medication?"=0A=0AFor some = people, that trade is absolutely worth it. =0A=0ASomeone with food addictio= n, alcohol use disorder, or severe metabolic disease is getting a benefit t= hat vastly outweighs the cost.=0A=0AHowever, in some people, you might be f= lattening out a reward system that was working just fine.=0A=0AAnd of cours= e, you know I had to say it.=0A=0AThis is why **fixing hormones first matte= rs so much**. =0A=0AIf your testosterone is in the gutter and your dopamine= response is already flat from low T, adding a GLP-1 on top of that is goin= g to make the anhedonia worse, not better. =0A=0AGet the foundation right b= efore reaching for the heavy artillery.=0A=0AThese drugs are tools. Powerfu= l ones. But every tool has a use case, and every use case has a cost. Under= stand both before you pick it up.=0A=0ABest,=0A=0AHunter Williams=0A=0A=E2= =80=94=E2=80=94=E2=80=94=E2=80=94=E2=80=94=E2=80=94=E2=80=94=E2=80=94=E2=80= =94=E2=80=94=E2=80=94=E2=80=94=E2=80=94=E2=80=94=E2=80=94=E2=80=94=E2=80=94= =E2=80=94=E2=80=94=E2=80=94=E2=80=94=E2=80=94=E2=80=94=E2=80=94=E2=80=94=E2= =80=94=E2=80=94=0A=0A**Source:**=0A=0AGodschall, E.N., Gungul, T.B., Sajoni= a, I.R., et al. _A brain reward circuit inhibited by next-generation weight= -loss drugs in mice._ Nature (2026). [https://doi.org/10.1038/s41586-026-10= 444-4](https://doi.org/10.1038/s41586-026-10444-4)=0A=0A=0A=E2=80=94=E2=80= =94=E2=80=94=0A=0AYou are reading a plain text version of this post. For th= e best experience, copy and paste this link in your browser to view the pos= t online:=0Ahttps://huntershealthhacks.beehiiv.com/p/the-double-edged-sword= -of-dopamine --dPzjRFRLR0yd1+YAIDzoEg Content-Type: text/html; charset="utf-8" Content-Transfer-Encoding: quoted-printable The Double-Edged Sword of Dopamine
New study on dopamine and GLP-1s  ‌ = ‌ ‌ ‌ ‌ ‌ ‌= 60;‌ ‌ ‌ ‌ ‌ ‌=  ‌ ‌ ‌ ‌ ‌ R= 04; ‌ ‌ ‌ ‌ ‌ &= #8204; ‌ ‌ ‌ ‌ ‌= 0;‌ ‌ ‌ ‌ ‌ ‌&= #160;‌ ‌ ‌ ‌ ‌ ̴= 4; ‌ ‌ ‌ ‌ ‌ &#= 8204; ‌ ‌ ‌ ‌ ‌ = ;‌ ‌ ‌ ‌ ‌ ‌&#= 160;‌ ‌ ‌ ‌ ‌ ‌= ; ‌ ‌ ‌ ‌ ‌ = 204; ‌ ‌ ‌ ‌ ‌ = ‌ ‌ ‌ ‌ ‌ ‌= 60;‌ ‌ ‌ ‌ ‌ ‌=  ‌ ‌ ‌ ‌ ‌ R= 04; ‌ ‌ ‌ ‌ ‌ &= #8204; ‌ ‌ ‌ ‌ ‌= 0;‌ ‌ ‌ ‌ ‌ ‌&= #160;‌ ‌ ‌ ‌ ‌ ̴= 4; ‌ ‌ ‌ ‌ ‌ &#= 8204; ‌ ‌ ‌ ‌ ‌ = ;‌ ‌ ‌ ‌ ‌ ‌&#= 160;‌ ‌ ‌ ‌ ‌ ‌= ; ‌ ‌ ‌ ‌ ‌ = 204; ‌ ‌ ‌ ‌ ‌ = ‌ ‌ ‌ ‌ ‌ ‌= 60;‌ ‌ ‌ ‌ ‌ ‌=  ‌ ‌ ‌ ‌ ‌ R= 04; ‌ ‌ ‌ ‌ ‌ &= #8204; ‌ ‌ ‌ ‌ ‌= 0;‌ ‌ ‌ ‌ ‌ ‌&= #160;‌ ‌ ‌ ‌ ‌ ̴= 4; ‌ ‌ ‌ ‌ ‌ &#= 8204; ‌ ‌
=
<= /table>
<= table role=3D"none" width=3D"100%" border=3D"0" cellspacing=3D"0" cellpaddi= ng=3D"0" align=3D"center">

May 11, 2026   |   Read online

The Double-Edged Sword of= Dopamine

New study on dopamine and GLP-1s

= <= /tr>
= <= td align=3D"center" valign=3D"middle" style=3D"border: 1px solid #E5E7EB; b= order-radius: 100%; width: 18px; height: 18px; padding: 8px;">3D"share<= /tr>
 
3D"share
 
3D"share=
 
3D"share
3D""
=

What they found is a brand new circuit, and it changes = how we should think about this entire class of medications.

= <= td align=3D"center" valign=3D"top" style=3D"padding:12px 19px 12px 19px;" c= lass=3D"dd">

Happy Monday!

A new paper just dropped in = Nature that finally explains something = the real-world data has been screaming for two years (Click here to read it).

People on GLP-1s are drinking less. Smoking less. Gambling less. Shopping = less. Some of them are saying food doesn't taste the same anymore.

Nobody knew why.

Until now.

The researchers built a humanized mouse that responds to the= small-molecule GLP-1s like orforglipron and danuglipron, then set out to f= ind what these drugs actually do in the brain.

Here's the short version. In addition t= o turning down hunger, GLP-1s turn down dopamine.

=

Specifically, they reduce dopamine rel= ease in the nucleus accumbens (the brain's main reward hub) when you ea= t something pleasurable.

Sam= e drug. Two faces. Let=E2=80=99s walk through it.

Two sentence summary:=C2=A0GLP= -1 drugs go beyond appetite suppression. They turn down dopamine across the= board, which is why they quiet cravings for alcohol, food, and gambling, a= nd also why some long-term users say their joy has gone flat.

<= /table>

This is genuinely huge for the addiction medicine world= .

<= td class=3D"dd" align=3D"left" style=3D"padding:0px 15px;text-align:left;wo= rd-break:break-word;">

The Downside

"I don't really get excited about things anymo= re."

<= /tr>
 

The New Circuit

For years, we've known GLP-1s wo= rk on the hindbrain and hypothalamus.

That's the "I'm full" signal. Classic homeosta= tic feeding.

This paper fou= nd a second circuit running in parallel.

Hindbrain =E2=86=92 central amygdala =E2=86=92 VTA =E2=86=92 = nucleus accumbens.

The cent= ral amygdala is the new piece. When the researchers selectively knocked out= the GLP-1 receptor in those amygdala neurons, the drugs basically lost the= ir ability to suppress pleasura= ble eating. Mice still got ful= l on normal chow. They just didn't lose interest in the high-fat food.<= /span>

So there are two parallel sy= stems running simultaneously.

One says, "Stop eating, you have enough calories."

The other says, "This isn't as = rewarding as you thought it was."

GLP-1s hit both.

 

Dopamine

<= /td>

This is the part that should grab your = attention.

They used a fluor= escent dopamine sensor implanted in the nucleus accumbens of live mice. The= n they fed the mice a high-fat diet and watched what happened in real time.=

Vehicle mice showed a big d= opamine spike at the moment of food retrieval. Classic reward signal. The k= ind of release that says "yes, do that again."

Mice on liraglutide, danuglipron, and orforgli= pron all showed the same thing.

A flatter peak. A smaller sustained release. Less dopamine, period.

This was true for all three drugs, peptide and small molec= ule alike. Which means it's a class effect, not specific to one compoun= d. The mechanism is built into how GLP-1 signaling works.

 

The Upside

If you&= #39;ve been paying attention to real-world data on semaglutide and tirzepat= ide, you've seen the reports.

Alcohol use disorder incidence drops in people who get prescribed the= se drugs.

Cannabis use disor= der drops.

People report les= s compulsive shopping, less doomscrolling, and less mindless late-night sna= cking.

For a long time, nobo= dy could explain it.

Some r= esearchers thought that weight loss alone improved mood.

Others thought it was the gut-brain axis doin= g something we hadn't mapped.

This paper gives us the actual receipts.

The drugs are blunting the reward signal coming from the= VTA into the accumbens. That's the same circuit that fires when an add= ict gets a hit. The same circuit that fires when you slam a pint of ice cre= am. The same circuit that fires when a slot machine pays out.

= Turn that signal down across the board, a= nd a lot of compulsive behavior loses its grip.

 

But the dopamine reduction isn't selective.

The drug doesn't know the difference= between a craving for vodka and a craving for your kid's birthday cake= .

It doesn't know the d= ifference between the dopamine surge from a junk-food binge and the dopamin= e surge from a meal with people you love.

It just turns the signal down.

So when you hear complaints from long-term GLP-1 users, th= e pattern starts making sense.

"Food doesn't taste the same."

"I lost weigh= t, but I also kind of lost my joy."

The mechanism does exactly what it's designed to do, just= applied to things you actually wanted to keep enjoying.

 
Final Thoughts

GLP-= 1s are the most important pharmaceutical development in metabolic medicine = in 40 years. I'm not going to pretend otherwise.

But we must stop talking about them like they'= re just appetite suppressants with some bonus benefits.

They're reward modulators. Appetite suppre= ssion is one downstream effect of a much larger mechanism.

If you're using one of these drugs, or t= hinking about it, the question to ask yourself isn't just "will th= is help me lose weight."

It's "am I okay turning down my dopamine response to everything= for the duration that I'm on this medication?"

For some people, that trade is absolutely wort= h it.

Someone with food add= iction, alcohol use disorder, or severe metabolic disease is getting a bene= fit that vastly outweighs the cost.

However, in some people, you might be flattening out a reward syste= m that was working just fine.

And of course, you know I had to say it.

This is why fixi= ng hormones first matters so much.

If your testosterone i= s in the gutter and your dopamine response is already flat from low T, addi= ng a GLP-1 on top of that is going to make the anhedonia worse, not better.=

Get the foundation right b= efore reaching for the heavy artillery.

These drugs are tools. Powerful ones. But every tool has a us= e case, and every use case has a cost. Understand both before you pick it u= p.

Best,

Hunter Williams

 

Source:<= /b>

Godschall, E.N., Gungul,= T.B., Sajonia, I.R., et al. A = brain reward circuit inhibited by next-generation weight-loss drugs in mice= . Nature (2026). https://doi.org/10.1038/s41586-026-= 10444-4

=
=
<= td align=3D"center" valign=3D"top" style=3D"padding-bottom:20px;padding-lef= t:15px;padding-right:15px;padding-top:20px; " class=3D"dd">
3D"ig"=3D=
<= img src=3D"https://media.beehiiv.com/cdn-cgi/image/fit=3Dscale-down,format= =3Dauto,onerror=3Dredirect,quality=3D80/uploads/asset/file/77285135-fcd3-48= e6-afed-97045dbefd05/beehiiv_profile_photo_large.png?t=3D1744125569" alt=3D= "" height=3D"auto" width=3D"189" style=3D"display:block;width:100%;border-r= adius:0px 0px 0px 0px;border-style:solid;border-width:0px 0px 0px 0px;box-s= izing:border-box;border-color:#E5E7EB;" border=3D"0"/>

Want more= ? Here=E2=80=99s how you can work with me:

=F0=9F=91=89Join my private co= aching group, The AXION Collective:

=F0=9F=91=89Try Zeroats, the w= orld=E2=80=99s first sugar-free, naturally flavored oatmeal:

=F0=9F=91=89Get the Pe= ptide Cheat Sheet:

<= h3 style=3D"color:#2A2A2A;font-weight:normal;mso-line-height-alt:125.0%;"><= span style=3D"font-size:1.5rem;">=F0=9F=91=89All my daily essentials on Ama= zon

=F0=9F=91=89Get discounts on your favorite peptides = and research chemicals:

= =F0=9F=91=8910% off the BEST workout supplements from Unmatched Supps (pre-= workout, whey protein, creatine, EAAs, electrolytes - use code HUNTERW at c= heckout):

=F0=9F= =91=89Submit A Video Topic For My Next YouTube Video:

<= tr style=3D"display: table-row !important;">

Update your email preferences = or unsubscribe here

<= p class=3D"copyright" style=3D"font-family:'Verdana',Geneva,sans-serif;colo= r:#2D2D2D!important;"> © 2026 Hunter's Health Hacks

228 = Park Ave S, #29976, New York, New York 10003, United States

<= table role=3D"none" border=3D"0" cellspacing=3D"0" cellpadding=3D"0" align= =3D"center" style=3D"display:table !important;">
= 3D"beehiivPowered by beehiiv
Terms of Service